Biological treatment for liver tumor and new potential biomarkers.
The search for effective and efficacious therapy for liver tumor was started many years ago and is still ongoing. Despite all of the surgical advances, much work needs to be done to improve understanding of the biology of the tumor and its treatment. The rules of hepatic surgery are changing because of two recent major trends: (1) technical simplification, and (2) the endeavor to treat an increasing number of patients. T lymphocytes are potent cellular effectors of the immune system and possess a memory that responds to rechallenge by the same antigen. Being more specific and less toxic than chemotherapy, tumor infusion could be an ideal adjuvant therapy for patients with primary and secondary liver malignancies. Moreover, tumor cell vaccines have demonstrated efficacy in terms of minimal residual disease and are being investigated, but the requirement for an adequate supple of autologos tumor may limit the general applicability of these approaches. Various studies have demonstrated the aberrant expression of germ-cell proteins called cancer-testis (CT) antigens in liver neoplastic cells. Their selective normal-tissue expression makes them ideal antigens for immune targeting of malignant disease. Specific expression of CT antigens also suggests their application as tumor markers to detect circulating hepatocellular carcinoma (HCC) cells, as an adjuvant diagnostic tool, and as indicators for recurrence and prognosis. Biological therapy is now generating more clinical trials. More studies need to be performed and further experiments need to be done, although currently this seems a valid pathway for the treatment of liver cancer. Cytoreduction treatment of liver tumor and the vaccine might be the future of the treatment of primary and secondary liver tumor.
Chiriva-Internati
Maurizio
M
Department of Microbiology and Immunology, Texas Tech University Health Science Center, Lubbock, TX 79430, USA. maurizio.chiriva@ttuhsc.edu
Grizzi
Fabio
F
Wachtel
Mitchell S
MS
Jenkins
Marjorie
M
Ferrari
Raffaele
R
Cobos
Everardo
E
Frezza
Eldo E
EE
D014408:Biomarkers, Tumor / Q000378:metabolism*; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D017115:Catheter Ablation; D003713:Dendritic Cells; D017048:Health Care Costs; D006498:Hepatectomy / Q000639:trends*; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D008113:Liver Neoplasms / Q000276:immunology / Q000378:metabolism / Q000628:therapy*
D014408:Biomarkers, Tumor
Ann Surg. 2000 Sep;232(3):381-91
10973388
Science. 1995 Nov 17;270(5239):1189-92
7502042
Ai Zheng. 2005 May;24(5):622-6
15890110
Br J Cancer. 2005 Mar 14;92(5):929-34
15756260
Science. 2006 Oct 6;314(5796):126-9
16946036
J Clin Oncol. 1985 Dec;3(12 ):1573-82
2415692
Proc Natl Acad Sci U S A. 1989 Sep;86(18):7159-63
2674949
J Immunol. 1993 May 15;150(10):4659-71
7683326
Nat Med. 1996 Dec;2(12):1361-6
8946836
Cancer Metastasis Rev. 1997 Jun;16(1-2):67-79
9156280
Aust N Z J Surg. 1990 Oct;60(10):811-7
2206121
J Immunol. 2000 Oct 1;165(7):4133-40
11034426
Surgery. 1990 May;107(5):511-20
2159190
Transplant Proc. 1993 Feb;25(1 Pt 2):1128-9
8382851
Br J Cancer. 2005 Aug 22;93(4):458-63
16106251
Cancer Lett. 2005 Mar 10;219(2):223-32
15723723
J Clin Lab Anal. 1991;5(5):344-66
1941355
Arch Surg. 1991 Mar;126(3):381-7
1998481
J R Coll Surg Edinb. 1997 Oct;42(5):303-9
9354061
Tumori. 1990 Feb 28;76(1):54-7
2181746
J Exp Med. 1989 Jan 1;169(1):309-14
2642530
Adv Cancer Res. 1995;67:155-95
8571814
Cancer. 1989 Jan 1;63(1):102-11
2642728
World J Gastroenterol. 2004 Jul 15;10(14):2034-8
15237429
J Exp Med. 1994 Apr 1;179(4):1109-18
8145033
Dig Dis Sci. 2004 Feb;49(2):224-7
15104361
Ann Surg. 1999 Jul;230(1):1-8
10400029
J Laparoendosc Adv Surg Tech A. 2007 Jun;17(3):282-4
17570770
Lancet. 1994 May 14;343(8907):1177-83
7909866
Proc Natl Acad Sci U S A. 1982 Aug;79(15):4718-22
6981814
Med Clin North Am. 1989 Jul;73(4):985-97
2542706
J Exp Med. 1995 Nov 1;182(5):1223-30
7595193
Cancer Res. 1989 Sep 1;49(17):4682-9
2547513
Zhonghua Bing Li Xue Za Zhi. 2005 Apr;34(4):202-5
16091172
J Transl Med. 2004 Jul 29;2(1):26
15283862
Int J Cancer. 2003 Dec 10;107(5):863-5
14566839
Immunology. 1990 Feb;69(2):282-6
1968427
World J Surg. 1997 Mar-Apr;21(3):330-42
9015180
Hepatology. 1996 May;23(5):1224-31
8621157
Ann Intern Med. 1988 Mar;108(3):390-401
2449110
Hepatology. 1996 May;23 (5):1181-8
8621152
Cancer Immun. 2002 Sep 19;2:11
12747756
World J Gastroenterol. 2005 Nov 14;11(42):6571-6
16425346
Hepatology. 1990 Apr;11(4):578-84
1691730
Dig Dis Sci. 2004 May;49(5):866-71
15259511
Cancer Gene Ther. 1997 Jan-Feb;4(1):17-25
9012447
J Clin Ultrasound. 1999 Jun;27(5):221-9
10355885
Lab Invest. 2003 Aug;83(8):1185-92
12920247
J Clin Oncol. 1996 Jun;14 (6):1787-97
8656247
Life Sci. 2006 Jul 17;79(8):744-8
16546222